Experimental combo for resistant leukemia shows early promise but trial halted
NCT ID NCT03146871
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The goal was to see if the combination was safe and tolerable. The trial was terminated early, so the full potential of this approach remains unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sEphB4-HSA fusion protein combined with azacitidine or decitabine
- What this could lead to
- If it works, this could point toward a new combination treatment for blood cancers that have stopped responding to standard therapy.
- What could go wrong
- This was a very small, early pilot study that was terminated early, so results are limited. The combination may not prove effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Precision radiation may boost stem cell transplant success in tough leukemias